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graphed ECV—15% total body volume. Patients are on a cardiac
monitor and observed during the 3–5 hour treatment. ECP is
performed 2 days in a row. Initially, we started every other week
and now have moved to starting weekly as we have noticed faster
improvement with this schedule. As symptoms improve, ECP
schedule is tapered. Seven patients have been treated (median age
13 years (9–28), 4 males/3 females). Median duration of ECP: 11
months (1–26). The procedure is well tolerated with mild symp-
toms of hypovolemia noted in patients 25 kg. Weight at start of
ECP was median 48 kg (22.2–79). Patients 25 kg have received
about 1 pRBC transfusion/month. All patients had failed standard
therapy with cyclosporine and prednisone in addition to a second-
or third-line agent. All were on prednisone at start of treatment.
Two patients have renal insufﬁciency. An attempt to lower pred-
nisone dose and discontinue other immunosuppression was made
after stabilization of cGVHD. Three patients expired due to
cGVHD complications. Of the remaining 4 patients: 1 is too early
to evaluate, all 3 others have responded, of which 2 have discon-
tinued steroid therapy. Response by organ and steroid doses are
listed below. All patients remain on a tapered schedule of ECP
(every 3 or 4 weeks) since ECP discontinuation led to cGVHD
ﬂares in 2, which responded with reinstitution of ECP. The pa-
tients with scleroderma and oral sensitivity appear to have had
signiﬁcant beneﬁt from ECP. ECP is feasible in pediatric patients
with cGVHD if hct and hydration are carefully maintained at
adequate levels for lower-weight patients. ECP appears to be
efﬁcacious for refractory cGVHD. Prospective studies are needed
to deﬁne treatment duration and schedule, and beneﬁts of using
ECP concurrently with other immunosuppressants. Finally, we
plan on demonstrating feasibility in patients20 kg using a similar
algorithm (Table 1).
Table 1. Pediatric Patients with Refractory CGVHD Treated with
Extracorporeal Photopheresis
Age
(yrs)
Duration
(mos)
Symptoms
at Diagnosis
Most
Recent
Symptoms
Intital and
Most
Recent
PDN
Dose, mg/
kg/d
Line
Type Outcome
Weight at
ECP Start
(kg)
12 7 Eyes,
mouth,
skin >
50%
Eyes-SD.
mouth-
CR, Skin-
PR
2 3 0.6 10F Double
Lumen
CVL
Dead 28.6
18 20 Liver Liver-CR 1.6 3 0 10 F single
lumen
CVL
Alive and
Well
48
20 11 Mouth, Skin
> 75%,
Liver
Mouth-PR,
skin-PR,
Liver-PD
0.5 3 0.5 9.6 F
Vortex
Port
Dead 79
11 3 Pulmonary Pulmonary-
PD
1 3 0.5 10 F
Double
Lumen
CVL
Dead 26
28 26 Skin > 50%
(Scleroderma)
Skin-PR 1 3 0.25 9.6 F
Vortex
port
Alive and
well
60.6
9 14 Skin > 50%
(Scleroderma)
Skin-PR 1 3 0 5 F Yuey
PIV
Placed
Before
Each
ECP
Alive and
Well
22.2
13 1 Liver Too Early
to
Evaluate
1 3 0.67 12 F
Double
Lumen
CVL
Alive and
Well
61.5
SD  stable disease, CR  complete response, PR  partial
response, PD  progressive disease, PDN  prednisone,
%body surface area.
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GRAVES’ DISEASE FOLLOWING UNRELATED UMBILICAL CORD BLOOD
TRANSPLANTATION IN PEDIATRIC PATIENTS
Driscoll, T.A.1, Ciocci, G.H.1, Kurtzberg, J.1 Pediatric Blood & Marrow
Transplant Program at Duke University Medical Center, Durham, NC.
Graves’ disease (GD) is the most prevalent autoimmune disease
in the United States with a peak incidence in the ﬁfth to sixth
decades of life and a female to male predominance of 10:1. In
recipients of allogeneic bone marrow and peripheral blood stem
cell transplants, GD recurs in previously affected recipients, occurs
in unaffected recipients by adoptive transfer of autoimmune thy-
roiditis from an affected donor, and occurs less frequently in
unaffected recipients transplanted with unaffected donors. GD was
diagnosed through laboratory surveillance in 3 male pediatric pa-
tients ages 5.5–14.3 years, 30–60 months after UCBT. All 3
affected patients received grafts from female donors and were full
donor chimeras. None had graft-versus-host disease (GvHD) at
diagnosis with GD. Two were transplanted for metabolic diseases
(ALD, PNP deﬁciency) and 1 for ALL. All were conditioned with
busulfan/ATG  cyclophosphamide (n  2) or melphalan (n  1)
and received cyclosporine and methylprednisolone for prophylaxis
against GvHD. All were off immunosuppression therapy for 	1
year at diagnosis of GD. Treatment with readioactive iodide (n 
2) and Propylthiouracil (n 1) corrected laboratory abnormalities.
The 3 boys were part of a cohort of 265 patients transplanted at our
center between 9/1993 and 9/2004, surviving for 	1 year post
UCBT. Within this group, 55% of the patients had female donors
and 45% had male donors. Interestingly, the three cases of GD
occurred among the 86 male patients who received female-donor
UUCBTs. No cases of GD were seen in female recipients. Neither
the donors nor mother of donors developed autoimmune diseases.
However, given their young ages, absence of disease does not rule
out the possibility of development of this disease several decades
into the future.The development of GD in 3 boys after UCBT
from female donors is interesting. The etiology of Graves’ Disease
remains incompletely understood but genetic susceptibility con-
tributes to the development of disease. One affected patient and its
donor expressed the GD susceptibility allele, HLA-DRB10301,
and conversely, a second affected patient and its donor expressed
the GD protective allele, DRB10701. This could indicate the
presence of other immunologic tendencies towards autoimmune
disease in the cord blood donor or an alloreactive process from
donor or low levels of maternal donor cells contaminating the
UCB graft. Further studies will be necessary to determine the
etiology of GD in these patients.
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RISK FACTORS FOR DEVELOPMENT OF SYMPTOMS AFTER AUTOLO-
GOUS TRANSPLANTATION FOR MULTIPLE MYELOMA
Campagnaro, E.1, Saliba, R.1, Anderson, K.1, Roden, L.1, Mendoza, F.1,
Aleman, A.1, Cleeland, C.1, Weber, D.1, Brown, J.1, Giralt, S.1 Blood
and Marrow Transplantation, University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Background: Multiple myeloma (MM) is the most common
indication for autografting in the United States. Although safe,
autografting can be associated with substantial morbidity due to
the toxic side effects of chemotherapy. Strategies aimed at mini-
mizing symptoms post autografting may result in better tolerance.
The risk factors for symptom development post autografting for
MM have not been well characterized. Purpose: To deﬁne pre-
transplant conditions, which may be predictive of post-transplant
symptom burden.Methods:We performed prospective evaluation
of symptom burden among 64 myeloma patients undergoing au-
tograft at MDACC as well as retrospective review of pretransplant
variables including patient demographics, performance status, al-
bumin, disease status, and Charlson Comorbidity Index (CCI).
Univariate analysis was performed to correlate pretransplant vari-
ables with post transplant symptom burden as deﬁned by M. D.
Anderson Symptom Inventory (MDASI) scores at different time
points post transplant. Results: 64 patients were studied from
6/2000 to 5/2003. Symptom burden increased from baseline to day
0 to nadir, with most patients returning to their baseline by day 30
post transplant. Table 1 summarizes the potential impact of pre-
transplant variables on median MDASI scores at nadir. Patients
with the highest MDASI scores at baseline had the highest MDASI
scores at nadir in quartile analysis (P  .001). Patients with Charl-
son score of 3, age 	 60, 2 microglobulin (2M) 	 3, albu-
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min  4, and female gender had a trend towards higher nadir
MDASI scores (see Table 1). Other pre-transplant variables, in-
cluding Durie-Salmon stage, LDH, hemoglobin, disease status at
time of autograft, and time from diagnosis to autograft had no
apparent correlation with symptom burden throughout transplant
(data not shown). Conclusions: Autografting for MM is associated
with signiﬁcant but reversible symptom burden during the ﬁrst 30
days of the procedure. Baseline symptom burden is the most
important predictor of post transplant symptom burden. Other
potential predictors include Charlson score, age, 2M, albumin,
and female gender. The MDASI scoring system is a potentially
useful means of following symptom burden post autografting that
could be used to assess interventions aimed at reducing transplant
related morbidity in MM patients (Table 1).
Table 1. Impact of Pre-transplant Variables on Nadir MDASI Scores
n Median (range) P value
Charlson score
<3 50 22 (1–97)
>3 14 41 (3–72) .09
Age
<60 43 23 (1–97)
>60 21 31 (3–72) .2
2M
< 3.0 34 20 (1–85)
>3.0 27 28 (4–97) .2
Albumin
< 4.0 50 27 (1–97)
> 4.0 14 19 (1–60) .2
Gender
Female 26 30 (5–85)
Male 38 23 (1–97) .2
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BLOOD AND MARROW TRANSPLANT CAREGIVER ORIENTATION AND
RESOURCE FAMILY PROGRAM
Jensen, S.L.1, Mignone, T.1, McCarthy, P.M.1 Roswell Park Cancer
Institute, Buffalo, NY.
Treatment advances have resulted in a dramatic increase in the
number of patients who survive hematological malignancies
through blood and marrow transplant, but the psychosocial aspects
of transplant and the emotional sequelae for the patient and the
family can be devastating. A number of studies have reported
signiﬁcantly increased rates of depression, anxiety, sexual dysfunc-
tion, and fatigue among the transplant population (eg, Antin, J.,
2002). Our experience has documented the need for a structured
program to prepare families for the challenges of the transplant
process.
The BMT Caregiver Orientation and Resource Family Pro-
gram. The goals of the Program:
• Help the caregiver to understand the patient’s medical/emo-
tional needs.
• Provide information to the caregiver so they can provide ade-
quate care to the patient.
• Assist the caregiver and patient in identifying and utilizing a list
of personal resources to help in the care of the patient. Provide
support to the caregivers, families, and patients.
BMT Caregiver Program: Each family receives a personalized
care manual during a two hour workshop for patients and caregiv-
ers. The workshop:
• Details the medical, psychological, and social implications of
transplant.
• Introduces them to their transplant team and their Resource
Family
• Helps them complete portions of their Family Workbook with
medical team present.
• Helps them understand the critical nature of caregiver support
and the importance of identifying and ameliorating caregiver
fatigue.
Resource Family Program: Resource Families are past trans-
plant patient families that have successfully navigated the rigors of
the disease treatment process. These families are educated to work
with new transplant patients and their families. Speciﬁc ways in
which the Resource Families help include:
• Sharing transplant experiences.
• Identifying and understanding stressors caregivers may encounter.
• Introducing techniques to manage the stress of the patient’s
illness and treatment.
The importance of preparing patients and their caregivers for the
care required after transplant cannot be understated and has a
direct relationship to the success of the transplant. This program
integrates the critical support needs of the caregiver with the
patient’s ongoing care. Program evaluation has been built into the
program to assess effectiveness. The current evaluation data, which
includes suggestions for program modiﬁcations from transplant
families, will be discussed.
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A QUALITY MANAGEMENT PROGRAM’S (QMP) FAVORABLE IMPACT ON
A HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) PRACTICE: THE
UNIVERSITY OF KANSAS MEDICAL CENTER EXPERIENCE
Deauna-Limayo, D.1, Shik, N.1, Merkel, D.1, Harvey, E.1,
Divine, C.1, Folker, T.1, Lewis, J.1, Hoffmann, T.1, Sherman, J.1,
Bradley, M.1, Skikne, B.1 The University of Kansas Medical Center,
Kansas City, KS.
HSCT remains the only curative option for some hematologic
disorders. However, it is associated with signiﬁcant toxicities. The
100-day transplant-related mortality (TRM) may range from 3 to
10% and 20 to 50%, among autologous and allogeneic transplant
recipients, respectively. We present the QMP’s favorable impact
on our institution’s stem cell transplant outcomes. QMP reorga-
nization was done pursuant to the Foundation for the Accredita-
tion of Cellular Therapy (FACT) standards. Transplant-related
aspects of care were identiﬁed and divided into 4 groups: clinical,
data management, data collection, and ﬁnancial. Members were
expanded, and active participation from our Infectious Control
service was solicited. Monthly audits of indicators from assigned
aspect of care were conducted. Outcome analyses of data gathered
from 2002 to 2004 were done. Internal and CIBMTR data served
as benchmarks. Internal audit(s) revealed infection as the leading
cause of early (30 days) TRM among 9/16 patients who under-
went allogeneic transplantation from September 2002 to Decem-
ber 2003, with documented bloodstream infection (BSI) in 55% of
the patients. A signiﬁcant increase in BSI during the fourth quarter
of 2004 were noted among patients in the Cancer/HSCT services
at 5.22 compared to 1.67/1000 patient days (internal benchmark).
Clostridium difﬁcile was increased in 2003, especially among HSCT
recipients: 11.8 versus 3.6/1,000 pt days in 2002. Working in close
collaboration with our Infectious Control service, contributory
factors were identiﬁed and changes implemented to improve out-
comes: construction of additional interventional radiology suite for
central venous catheter placement, especially for immunocompro-
mised patients, alteration of dressing change techniques, updating
of infection control policies, and hiring of a dedicated transplant
nurse practitioner. Follow-up data revealed a decrease of BSI
to1.72/1,000 pt days in the ﬁrst quarter 2005. C. difﬁcile incidence
trended down to 10/1000 pt days in 2004. The 2003 and 2004
100-day TRM showed signiﬁcant decrease from 18% to 4%
among autologous and 45% to 20% for allogeneic transplant
recipients, respectively. Median neutrophil and platelet engraft-
ments were 11.4 and 17 days for autologous transplants, and 16.5
and 21 days for allogeneic transplants, at par with CIBMTR data
serving as benchmark. In summary, reorganization of our QMP
favorably impacted our transplant practice. A multi-disciplinary
approach is essential.
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